Follow a botanical antimicrobial protocol optimized for Eurasian Borrelia species

A structured 28-day botanical antimicrobial ramp-up protocol combined with biofilm disruption, optimized for Eurasian borreliosis (B. garinii and/or B. afzelii). Herb selection and sequencing prioritize compounds with direct in vitro evidence against B. garinii morphological forms, particularly its dense layered biofilm which is structurally more resistant than B. burgdorferi biofilm.

Why a Eurasian-Specific Protocol

B. garinii and B. afzelii share only 26.1% core genome overlap with B. burgdorferi (Brglez et al. 2025). Most botanical antimicrobial research was conducted exclusively on B. burgdorferi strain B31 (North American). The Goc et al. studies (2015, 2016, 2019) are the only published work testing compounds against B. garinii across all three morphological forms (spirochetes, round bodies, biofilm), revealing that B. garinii forms a denser, layered biofilm requiring different compounds and 1.5–2x higher concentrations than B. burgdorferi's scattered colony-like biofilm.

This protocol leads with compounds that have direct Eurasian-species evidence.

Protocol Structure

Three tracks are introduced in sequence to minimize Herxheimer reactions and isolate tolerance issues:

Days	Track	Action	Details
1–3	Biofilm	Disruptors only	NAC + serrapeptase + nattokinase + stevia at half dose
4–6	Tier 1	+ Chinese skullcap ½ dose	Only herb tested against B. garinii across all 3 forms
7–9	Tier 1	Skullcap → full	+ Monolaurin ½ dose
10–12	Tier 1	Monolaurin → full	Biofilm → full dose, + knotweed ½ dose
13–15	Tier 1	Knotweed → full	+ Cat's claw ½ dose
16–20	Tier 1	All Tier 1 at full dose	Settle into routine
21–28	Tier 2	+ Tier 2 herb(s)	Full protocol by Day 28

Days 1–3: Biofilm Disruptors Only

Take on an empty stomach each morning. No antimicrobial herbs yet — give the disruptors a head start weakening the biofilm matrix. B. garinii biofilm is denser and more layered than B. burgdorferi biofilm, so pre-loading disruptors before antimicrobials is especially important.

• NAC 600 mg
• Serrapeptase 60,000 SPU (enteric-coated)
• Nattokinase 1,000 FU
• Stevia whole-leaf extract: 1 dropper in water
• Drink 3+ liters water daily throughout the entire protocol

Days 4–6: First Herb — Chinese Skullcap (Baicalein)

Continue biofilm disruptors at half dose. Add:

• Chinese skullcap (baicalein): 250 mg 2x/day with meals

Chinese skullcap leads this protocol because it is the only compound tested against B. garinii across all three morphological forms — spirochetes, round bodies, and biofilm (Goc et al. 2015). Baicalein reduced B. garinii biofilm by 40–60% at 200–500 µg/mL and showed no significant cytotoxicity to human HepG2 cells. Monitor for Herxheimer reaction (temporary worsening from bacterial die-off).

Days 7–9: Skullcap Full + Monolaurin

• Chinese skullcap: increase to 500 mg 3x/day with meals
• Monolaurin: 300 mg 2x/day with meals

Monolaurin is one of only two compounds (alongside baicalein) shown effective against B. garinii biofilm in vitro (Goc et al. 2015). It is a fatty acid monoglyceride derived from coconut oil that disrupts bacterial membranes. Effective at ≥500 µg/mL against B. garinii biofilm with no significant cytotoxicity to human cells up to 125 µg/mL.

Days 10–12: Monolaurin Full + Biofilm Full + Japanese Knotweed

• Monolaurin: increase to 600 mg 3x/day with meals
• Biofilm disruptors to full dose: NAC 600 mg 2x/day, serrapeptase 120,000 SPU morning, nattokinase 2,000 FU morning, stevia 1–2 droppers 2x/day
• Japanese knotweed: 250 mg 2x/day with meals

Japanese knotweed (resveratrol) showed activity against B. garinii spirochetes in vitro, though with minimal activity against round bodies and no significant activity against biofilm. Combined with the biofilm-active baicalein and monolaurin already introduced, knotweed adds complementary spirochetal coverage.

Days 13–15: Knotweed Full + Cat's Claw

• Japanese knotweed: increase to 500 mg 3x/day with meals
• Cat's claw: 250 mg 2x/day with meals

Cat's claw has demonstrated antimicrobial activity against B. burgdorferi morphological forms (proanthocyanidins) and immunomodulatory properties. While not tested directly against Eurasian species, its immunomodulatory effects are species-independent.

Days 16–20: All Tier 1 at Full Dose

• Cat's claw: increase to 500 mg 3x/day
• All four Tier 1 herbs now at full dose. Settle into the routine.

Days 21–28: Add Tier 2 Herbs

Choose one or two based on clinical picture:

• Cryptolepis tincture — the strongest single agent against B. burgdorferi persisters (complete eradication in Feng et al. 2020). Has not been tested against Eurasian species, but possesses broad-spectrum antimicrobial activity. Start at ½ tsp 2x/day, increase to 1 tsp 3x/day.
• Black walnut green hull tincture — active against stationary-phase B. burgdorferi. Start at ½ tsp 2x/day, increase to 1 tsp 3x/day.
• Artemisia annua 500 mg — if Babesia co-infection suspected (night sweats, air hunger, temperature dysregulation)
• Allicin (stabilized garlic) 450 mg — disrupts biofilm quorum sensing

Start Tier 2 at half dose on Day 21, increase to full dose by Day 24. A second Tier 2 herb may be added at Day 27.

Full Daily Schedule (Day 28 Onward)

Time	Take
6:30 AM empty stomach	NAC 600 mg + serrapeptase 120K SPU + nattokinase 2K FU
7:00 AM breakfast	Chinese skullcap 500 mg + monolaurin 600 mg + knotweed 500 mg + cat's claw 500 mg + Tier 2 herb(s) + stevia 1–2 droppers
12:00 PM lunch	Chinese skullcap 500 mg + monolaurin 600 mg + knotweed 500 mg + cat's claw 500 mg + Tier 2 herb(s)
6:00 PM dinner	Chinese skullcap 500 mg + monolaurin 600 mg + knotweed 500 mg + cat's claw 500 mg + stevia 1–2 droppers
9:00 PM	NAC 600 mg

Monitoring Checkpoints

Week 8: Test CRP and compare to baseline. Review symptoms journal.

• CRP dropped more than 30%: continue protocol
• CRP dropped 10-30%: continue, retest at Week 12
• No change: continue to Week 12 before deciding

Week 12: Test CRP again. This is the key decision point.

• CRP dropping + symptoms improving: continue 3–6 more months
• CRP stable + mixed symptoms: continue 3 months, consider swapping Tier 2 herbs
• No CRP change + no improvement: protocol is not working — seek medical evaluation
• CRP rising + symptoms worse: stop all antimicrobials immediately and see a doctor

Tapering (After 6–9 Months of Response)

Drop herbs one at a time with 2-week observation gaps: Tier 2 herbs first, then cat's claw, Japanese knotweed, monolaurin, and Chinese skullcap last (strongest Eurasian-species evidence). If symptoms return after dropping a herb, resume it for 2 more months before trying again. Continue biofilm disruptors for 4 weeks after the last herb is stopped. Test CRP at 2 weeks and 4 weeks after full stop.

Herxheimer Reaction Management

Worsening symptoms in weeks 1–3 indicates bacterial die-off and is expected. Manage with:

• Activated charcoal 500 mg taken 2+ hours away from all herbs (charcoal absorbs everything indiscriminately)
• Increase water to 4+ liters/day
• Temporarily halve herb doses for 2–3 days, then resume full dose
• Do not stop entirely unless symptoms are severe — stopping removes antimicrobial pressure and allows surviving bacteria to repopulate

Stop and seek medical help if: fever above 103°F / 39.4°C, difficulty breathing, severe chest pain, or symptoms worsen continuously beyond Week 3 with no improvement.

Important Limitations

• All supporting research is in vitro (laboratory). One in-vivo human study (Diederich et al. 2024, 452 European Lyme patients) showed botanical antibiotics were as effective as conventional antibiotics in reducing disease activity measured by LTT — but was not specific to this protocol.
• No compound in this protocol has been tested against B. afzelii. Dipsacus sylvestris (teasel) is the only herb with B. afzelii data (>95% growth inhibition of planktonic forms) but is not included due to limited evidence scope (no biofilm or round-body activity).
• Cryptolepis and black walnut (Tier 2 in this protocol) have only been tested against B. burgdorferi. Their inclusion is based on broad-spectrum antimicrobial activity and shared Borrelia genus biology.
• NAC evidence against Borrelia biofilms is extrapolated from its documented activity against biofilms of other bacterial species.
• This protocol does not replace conventional antibiotic treatment for confirmed acute Lyme disease or neuroborreliosis.
• Individual responses vary. What works in a test tube may not work identically in the body.

Research Basis

Herbs in this protocol were selected based on published research, prioritizing studies that tested against Eurasian Borrelia species:

• Goc et al. (2015), Journal of Applied Microbiology — tested 15 phytochemicals against all three morphological forms (spirochetes, round bodies, biofilm) of both B. burgdorferi and B. garinii. Baicalein and monolaurin were the only compounds effective against B. garinii biofilm (40–60% reduction). B. garinii biofilm was structurally denser (layered assembly vs scattered colonies), requiring 1.5–2x higher concentrations than needed for B. burgdorferi.
• Goc et al. (2016), International Journal of Biological Sciences — doxycycline combined with baicalein showed additive effects against all morphological forms of both B. burgdorferi and B. garinii.
• Goc et al. (2019), BMC Complementary Medicine and Therapies — tested 47 oils and fatty acids against both B. burgdorferi and B. garinii. Bay leaf oil and cassia oil (cinnamaldehyde) were the only oils effective against biofilm of both species (20–30% reduction).
• Feng et al. (2020), Frontiers in Medicine — tested 12 botanical medicines against B. burgdorferi only. Cryptolepis was the only agent to achieve complete eradication of stationary-phase Borrelia. Japanese knotweed, black walnut, cat's claw, and Chinese skullcap also showed significant persister activity.
• Theophilus et al. (2015), European Journal of Microbiology and Immunology — whole-leaf stevia extract reduced Borrelia biofilm by 40% on plastic and 34% on collagen surfaces.
• Diederich et al. (2024), Gavin Publishers — retrospective in-vivo study of 452 European Lyme patients. Botanical antibiotics were as effective as conventional antibiotics in reducing disease activity (LTT-SI), while untreated patients worsened.
• Brglez et al. (2025), Frontiers in Cellular and Infection Microbiology — genomic characterization of biofilm-forming B. afzelii and B. garinii showing only 26.1% core genome overlap with B. burgdorferi and that biofilm formation markedly decreases antibiotic efficacy.